NO963029L - Anvendelse av IL-10 for å stimulere cytologisk aktivitet av enkjernete celler i perifert blod - Google Patents

Anvendelse av IL-10 for å stimulere cytologisk aktivitet av enkjernete celler i perifert blod

Info

Publication number
NO963029L
NO963029L NO963029A NO963029A NO963029L NO 963029 L NO963029 L NO 963029L NO 963029 A NO963029 A NO 963029A NO 963029 A NO963029 A NO 963029A NO 963029 L NO963029 L NO 963029L
Authority
NO
Norway
Prior art keywords
peripheral blood
stimulate
blood cells
core peripheral
cytological activity
Prior art date
Application number
NO963029A
Other languages
English (en)
Other versions
NO963029D0 (no
Inventor
Martin A Schwarz
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO963029D0 publication Critical patent/NO963029D0/no
Publication of NO963029L publication Critical patent/NO963029L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Denne oppfinnelsen vedrører anvendelse av IL-10, alene eller i kom- binasjon med IL-2 og/eller a-lFN, til å behandle neoplasmasykdommer ved å sti- mulere cytolytisk aktivitet av mono- nukleære celler fra perifert blod.
NO963029A 1994-01-20 1996-07-19 Anvendelse av IL-10 for å stimulere cytologisk aktivitet av enkjernete celler i perifert blod NO963029L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN94194863A CN1142186A (zh) 1994-01-20 1994-01-20 用白介素-10激活外周血单核细胞的细胞溶解活性
PCT/IB1994/000008 WO1995019780A1 (en) 1994-01-20 1994-01-20 Use of il-10 to stimulate peripheral blood mononuclear cell cytolytic activity

Publications (2)

Publication Number Publication Date
NO963029D0 NO963029D0 (no) 1996-07-19
NO963029L true NO963029L (no) 1996-09-19

Family

ID=37708148

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963029A NO963029L (no) 1994-01-20 1996-07-19 Anvendelse av IL-10 for å stimulere cytologisk aktivitet av enkjernete celler i perifert blod

Country Status (10)

Country Link
EP (1) EP0740552A1 (no)
JP (1) JPH09508116A (no)
CN (1) CN1142186A (no)
AU (1) AU707019B2 (no)
FI (1) FI962813A (no)
NO (1) NO963029L (no)
NZ (1) NZ259584A (no)
PL (1) PL175343B1 (no)
SK (1) SK91696A3 (no)
WO (1) WO1995019780A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140142A2 (en) 1998-12-22 2001-10-10 Schering Corporation Treatment of hepatitis c virus infections with interleukin-10
AU2001296962A1 (en) 2000-09-29 2002-04-08 Schering Corporation Pegylated interleukin-10
RU2322452C2 (ru) * 2006-03-27 2008-04-20 Михаил Николаевич Смирнов Иммуномодулирующая композиция
BRPI0719446A2 (pt) * 2006-09-28 2013-12-10 Schering Corp Uso de il-10 peguilada para tratar câncer
WO2009003185A1 (en) * 2007-06-27 2008-12-31 Joslin Diabetes Center, Inc. Regulatory t cells in adipose tissue
JP5888980B2 (ja) 2008-12-17 2016-03-22 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． モノ−およびジ−ｐｅｇｉｌ１０の製造および用途
CA2908198A1 (en) 2013-04-18 2014-10-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
AU2014311432A1 (en) 2013-08-30 2016-03-03 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
MX2016005915A (es) 2013-11-11 2016-12-16 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
CN107001438A (zh) 2014-10-14 2017-08-01 阿尔莫生物科技股份有限公司 白细胞介素‑15组合物及其用途
CN107106655A (zh) 2014-10-22 2017-08-29 阿尔莫生物科技股份有限公司 使用白细胞介素‑10治疗疾病和病症的方法
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
EP3302547A1 (en) 2015-05-28 2018-04-11 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
WO2017035232A1 (en) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2023072861A1 (en) * 2021-10-25 2023-05-04 Ellennbe Gmbh Pharmaceutical composition and kit comprising an immunomodulatory substance for treating diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY108267A (en) * 1991-01-16 1996-09-30 Schering Corp Use of interleukin-10 in adoptive immunotherapy of cancer
CA2100553A1 (en) * 1991-01-16 1992-07-17 Paulo J. M. Vieira Treatment of neoplastic disease with interleukin-10
US5055045A (en) * 1991-03-18 1991-10-08 Dickie Robert G Disposable dental matrix retainer clamp

Also Published As

Publication number Publication date
JPH09508116A (ja) 1997-08-19
CN1142186A (zh) 1997-02-05
EP0740552A1 (en) 1996-11-06
NZ259584A (en) 1998-01-26
PL315513A1 (en) 1996-11-12
WO1995019780A1 (en) 1995-07-27
FI962813A0 (fi) 1996-07-11
SK91696A3 (en) 1997-04-09
AU707019B2 (en) 1999-07-01
NO963029D0 (no) 1996-07-19
FI962813A (fi) 1996-07-11
AU5842594A (en) 1995-08-08
PL175343B1 (pl) 1998-12-31

Similar Documents

Publication Publication Date Title
NO963029L (no) Anvendelse av IL-10 for å stimulere cytologisk aktivitet av enkjernete celler i perifert blod
EA200600076A1 (ru) Композиции и способы увеличения активности теломеразы
DK545584D0 (da) Enzym-resistente immonumodulatoriske peptider
ATE153856T1 (de) Zusammensetzung zur stimulierung des immunsystems
NO990916L (no) Bruk av GLP-1 eller analoger i behandlingen av myokardialt infarkt
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
KR950700333A (ko) 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로부터의 제조 방법(improved alpha interferon composition and method for its production from human peripheral blood leukocytes)
FR2777183B1 (fr) Utilisation d'au moins un hydroxystilbene dans une composition destinee a favoriser la desquamation de la peau et composition le comprenant
NZ314839A (en) 1,25-Dihydroxy-16,23Z-diene-20-epi-16-ene-cholecalciferol (Vitamin D3) analogues
NZ332720A (en) Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
EP0211354A3 (en) Nucleosides and their use as antineoplastic agents
GB2187955B (en) Improvements in or relating to the treatment of sickle cell disease
DE69725882D1 (de) Adenovirus e4 proteine für induktion von zelltod
PH27214A (en) N-2,3-butadienyl tri and tetraaminoalkane derivatives
BG101126A (en) The use of muramylpeptide compounds
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups
HU9201197D0 (en) Protection from shock subsequent to injury by double-stranded rns
EP0967276A3 (en) Anti-tumor agent comprising salmosin
MY131599A (en) Use of il-10 to stimulate peripheral blood mononuclear cell cytolytic activity
PT1032402E (pt) Uso de citicolina para o tratamento de esclerose multipla
WO2005094282A3 (en) Combination therapy comprising cloretazinetm
DE3374066D1 (en) N-acyl derivatives of peptides, their manufacture and use in combating diseases and means therefor
JPS6485990A (en) Antihypertestoeronemia agent
IL136807A0 (en) Topical carbamazepine formulation and methods of use
EP0321094A3 (en) Treatment of factor viii inhibitors